The deubiquitinating enzyme STAMBP is a newly discovered driver of triple-negative breast cancer progression that maintains RAI14 protein stability

Qianqian Yang1,2,4, Ding Yan1,2,4, Chaoying Zou1,2, Qian Xue1,2, Shuhui Lin1,2, Qingtian Huang1,2, Xiaofen Li1,2, Daolin Tang3, Xin Chen1,2✉, and Jinbao Liu1,2✉

© The Author(s) 2022

Triple-negative breast cancer (TNBC) is a heterogeneous malignancy in women. It is associated with poor prognosis, aggressive malignant behavior, and limited treatment options. In the ubiquitin–proteasome system (UPS), deubiquitinases (DUBs) are potential therapeutic targets for various tumors. In this study, by performing unbiased siRNA screening, we identified STAMBP, a JAMM metalloprotease in the DUB family, as a driver of human TNBC tumor growth. Functionally, the knockdown of STAMBP inhibited the proliferation, migration, and invasion of multiple TNBC cell lines. Immunoprecipitation–mass spectrometry combined with functional and morphological analysis verified the interaction between STAMBP and the actin-binding protein RAI14. Mechanistically, STAMBP stabilized the RAI14 protein by suppressing the K48-linked ubiquitination of RAI14 and thus prevented its proteasomal degradation. Therefore, knocking down STAMBP resulted in the reduction in RAI14 protein levels and suppression of tumor growth in vitro and in vivo. Importantly, high levels of STAMBP were correlated with poor prognosis in TNBC patients. In summary, we reveal a previously unrecognized DUB pathway that promotes TNBC progression and provides a rationale for potential therapeutic interventions for the treatment of TNBC.

Experimental & Molecular Medicine (2022) 54:2047–2059; https://doi.org/10.1038/s12276-022-00890-1

INTRODUCTION
Breast cancer is the most commonly diagnosed malignancy and one of the leading causes of cancer-related deaths in women worldwide. As a highly heterogeneous disease, breast cancer can be classified into five subtypes based on its genetic and histopathological features. These types include basal-like/triple-negative breast cancer (TNBC), luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and normal-like breast cancer. TNBC is characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or epidermal growth factor receptor 2 (HER2)-enriched, and normal-like breast cancer. TNBC is associated with poor prognosis, aggressive malignant behavior, and limited treatment options. In the ubiquitin–proteasome system (UPS), deubiquitinases (DUBs) are potential therapeutic targets for various tumors. In this study, by performing unbiased siRNA screening, we identified STAMBP, a JAMM metalloprotease in the DUB family, as a driver of human TNBC tumor growth. Functionally, the knockdown of STAMBP inhibited the proliferation, migration, and invasion of multiple TNBC cell lines. Immunoprecipitation–mass spectrometry combined with functional and morphological analysis verified the interaction between STAMBP and the actin-binding protein RAI14. Mechanistically, STAMBP stabilized the RAI14 protein by suppressing the K48-linked ubiquitination of RAI14 and thus prevented its proteasomal degradation. Therefore, knocking down STAMBP resulted in the reduction in RAI14 protein levels and suppression of tumor growth in vitro and in vivo. Importantly, high levels of STAMBP were correlated with poor prognosis in TNBC patients. In summary, we reveal a previously unrecognized DUB pathway that promotes TNBC progression and provides a rationale for potential therapeutic interventions for the treatment of TNBC.

Published online: 25 November 2022

Received: 2 March 2022 Revised: 13 September 2022 Accepted: 19 September 2022

© The Author(s) 2022

STAMBP is a newly discovered metalloprotease in the DUB family, as a driver of human TNBC tumor growth. Functionally, the knockdown of STAMBP inhibited the proliferation, migration, and invasion of multiple TNBC cell lines. Immunoprecipitation–mass spectrometry combined with functional and morphological analysis verified the interaction between STAMBP and the actin-binding protein RAI14. Mechanistically, STAMBP stabilized the RAI14 protein by suppressing the K48-linked ubiquitination of RAI14 and thus prevented its proteasomal degradation. Therefore, knocking down STAMBP resulted in the reduction in RAI14 protein levels and suppression of tumor growth in vitro and in vivo. Importantly, high levels of STAMBP were correlated with poor prognosis in TNBC patients. In summary, we reveal a previously unrecognized DUB pathway that promotes TNBC progression and provides a rationale for potential therapeutic interventions for the treatment of TNBC.

The classical DUBs can be categorized into six subclasses: ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific proteases (USPs), ovarian-tumor proteases (OTUs), Machado–Joseph disease protein domain proteases (MJDs), the monocyte chemoattractant protein-induced protein (MCPIP), and Zn-dependent JAMM/MPN domain–associated metalloproteases (JAMMs). Among the DUBs, STAM-binding protein (STAMBP) belongs to the JAMM metalloprotease subfamily. STAMBP acts as an endosome-
associated DUB by interacting with the SH3 domain of STAM, a component in the endosomal sorting complexes required for transport (ESCRT) machinery. STAMB synthesis causes microcephaly–capillary malformation syndrome, which is associated with elevated levels of ubiquitin protein aggregates. STAMB promotes inflammasome activity in innate immune responses by mediating the deubiquitination of NALP7 and preventing the transport of NALP7 to lysosomes, thereby increasing NALP7 abundance. STAMB also inhibits excessive activation of the inflammasome by preventing the nondegradative ubiquitination of NLRP3. STAMB may promote the stabilization of Unc-51-like autophagy-activating kinase 1 (ULK1) by removing its K48-linked ubiquitin chains, thereby participating in the regulation of autophagic flux. Although STAMB has been implicated in the tumor metastasis of lung adenocarcinoma and melanoma, the pathological role of STAMB in TNBC has not been elucidated.

In this study, we identified a previously unrecognized role of STAMB in regulating the proteasomal degradation of retinoic acid-induced 14 (RAI14; an actin-binding protein) in human TNBC cells. STAMB favors the growth of TNBC by removing the ubiquitination of RAI14 and enhancing its stability in vitro and in vivo. In a clinical setting, overexpressed STAMB was associated with poor clinical outcomes in TNBC. Hence, our data provide the first evidence for the pathological role of STAMB in TNBC.

### MATERIALS AND METHODS

#### Cell lines and cell culture

The MDA-MB-231 and BT549 human breast cancer cell lines were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The MDA-MB-231 and BT549 cells were cultured in DMEM/F12 and DMEM, respectively, with 10% fetal bovine serum (FBS). These cell lines were grown in an incubator maintained at 37°C with 5% CO2. All the cells were mycoplasma-free and authenticated using short tandem repeat (STR) typing analysis.

#### Reagents and primary antibodies

Bafilomycin A1 (S1413), cycloheximide (S7418), and MG132 (S2619) were purchased from Selleck Chem (Houston, TX, USA). Anti-STAMB (sc-271641) and anti-ubiquitin (sc-8017) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-RAI14 (ab137118), anti-MMP9 (ab137867), and anti-FAPBPC1 (10970-1-AP) antibodies were purchased from Abcam (UK). Anti-K48-ub (S5151) and anti-HA-tag (3724S), anti-DYKDDDDK (FLAG) tag (14793), E-Cadherin (3195T), Slug (9585T), Vimentin (5741), and anti-GAPDH (5174) antibodies were purchased from Abcam (USA). Anti-RAI14 (ab137118), anti-MMP9 (S5151), and anti-FAPBPC1 (10970-1-AP) antibodies were purchased from Abcam (UK). Anti-K48-ub (S5151) and anti-HA-tag (3724S), anti-DYKDDDDK (FLAG) tag (14793), E-Cadherin (3195T), Slug (9585T), Vimentin (5741), and anti-GAPDH (5174) antibodies.

#### siRNA transfection

The siGENOME SMARTpool siRNA Library of human deubiquitinating enzymes was obtained from Dharmacon-Horizon Discovery (Cambridge, England). RAI14 siRNAs were purchased from GenePharma (Shanghai, China). The sequences of the RAI14 siRNAs were as follows (all are shown in the 5’-3’ orientation): RAI14 siRNA-1: sense: GGAUGGUAGAGCGCCAGAAtt, anti-sense: AUUCUGGCGUCUGACAUCCtt; and RAI14 siRNA-2: sense: GCGUAUGCUCUAUGAAGGtt, anti-sense: UAUCCAAAGUAGUCAGCtt. Exponentially proliferating cells were seeded in dishes or well plates for 24 h. siRNAs (50 nM) were mixed with Lipofectamine 3000 transfection reagent according to the manufacturer’s instructions (Invitrogen, L3000015). After 15 min of incubation, this mixture was added to each well in the dark, and the cells were incubated for 24 h. siRNA transfection efficiency was assessed by western blotting.

#### Transwell assays

Cells were plated at a density of 2 × 10^5 cells/well and cultured for 24 h. A total of 0.5–1 × 10^5 cells in PBS-free medium were plated in the upper chamber of Transwell inserts (Corning, 3422), and medium with 10% FBS was added to the lower insert chamber. After 24 h of incubation, the chambers were washed with PBS and fixed with paraformaldehyde. Then, the cells remaining on the upper side of the Transwell inserts were wiped off with a cotton swab. The cells were stained with 1% crystal violet for 5–10 min. All experiments were performed in, at least, triplicate.

#### Wound healing assays

Cell migration was evaluated by wound healing assays. Cells were plated at a density of 2 × 10^5 cells/well and cultured for 24 h. Cell growth was recorded at 24 h after scratching. Then, the percentage of cell wound healing was analyzed by Image-Pro Plus 7 software. All experiments were performed in, at least, triplicate.

#### Quantitative RT-PCR

RNA was extracted from cells with RNAiso Plus (TaKaRa, 9108) according to the manufacturer’s instructions. The RNA concentration was adjusted to be equal in each group, and a PrimeScript RT Mx Master Mix kit (TaKaRa, RR036B) was used to synthesize first-strand cDNA. The mRNA levels of STAMB, RAI14, and GAPDH were measured using real-time quantitative PCR with a SYBR Premix Ex Taq kit (TaKaRa, RR820A). The primers for PCR in this study are listed in Supplementary Table 1.
Coimmunoprecipitation
Cell lysates were prepared with cell lysis buffer (Cell Signaling Technology, 9803) and protease inhibitors. Each specific antibody was mixed with Dynabeads (Invitrogen, 14311D) and incubated for at least 16 h with rotation. Protein concentrations were adjusted to 2 μg/μl. The mixtures of proteins and Dynabeads containing the required antibodies were incubated with rotation at 4 °C for 1 h. After 3 washes with PBS containing 0.5% Tween 20 (PBS-T), the mixtures were resuspended in an SDS loading buffer. After boiling in a water bath for 10 min and centrifugation at 4 °C for 3 min, the supernatant was collected for further analysis.

Immunofluorescence analysis
MDA-MB-231 and BT549 cells were plated on chamber slides (Thermo Fisher Scientific, 177402) and cultured for 24 h. After 3 washes with PBS containing...
Fig. 1 STAMBP promotes proliferation, migration, and invasion of TNBC cells. a, b Identification of STAMBP as a carcinogenic deubiquitinase in breast cancer cells. BT549 cells were transfected with 96 deubiquitinase siRNAs for 72 h, and cell proliferation was determined by MTS assay. “DUB gene rank position” means ranking DUBs from 1 (lowest) to 96 (highest) according to the relative cell viability, which is calculated by the following formula: log2 (siDUB/siNC ratio). c MDA-MB-231 and BT549 cells were stably transfected with two individual STAMBP shRNAs or control shRNA. STAMBP expression in cells was measured by Western blotting. d-f The proliferation, migration, and invasion of MDA-MB-231 and BT549 cells stably transfected with two individual STAMBP shRNAs or control shRNA for the indicated times were determined by MTS assays (d), wound healing assays (e), and Transwell migration assays (f), respectively. Representative images are shown. Scale bars: 50 μm. The mean ± SD (n = 3). *p < 0.05 compared to the NC. 

g MDA-MB-231 and BT549 cells stably expressed vector or Flag-STAMBP. STAMBP protein expression in cells was measured by Western blotting. h–j Cell proliferation, migration, and invasion of MDA-MB-231 and BT549 cells stably transfected with vector or Flag-STAMBP for the indicated times were determined by MTS assays (h), wound healing assays (i), and Transwell migration assays (j), respectively. Representative images are shown. Scale bars: 50 μm. The wound healing percentage and cell migration percentage with different treatments were quantified with Image-Pro Plus 7 software.

Fig. 2 STAMBP interacts with RAI14. a MDA-MB-231 cell lysates were incubated with beads conjugated with anti-STAMBP antibodies. Immunoprecipitates were analyzed by mass spectrometry. b Ambipolar ion peaks of the indicated proteins are shown. c Immunoblot analysis of the indicated protein expression in MDA-MB-231 and BT549 cells stably transfected with two individual STAMBP shRNAs or control shRNA. d Endogenous STAMBP and RAI14 interactions were detected by coimmunoprecipitation in MDA-MB-231 and BT549 cells. e The cellular location of STAMBP (green) and RAI14 (red) in MDA-MB-231 and BT549 cells was examined by immunofluorescence staining using STAMBP and RAI14 antibodies and visualized by fluorescence microscopy. DAPI (4′,6-diamidino-2-phenylindole) was used to stain nuclei. Scale bars: 10 μm.
the cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.1% Triton X-100 for 5 min. Then, 5% bovine serum albumin (Sigma, A8806) was used to block the cells for 30 min. After washing with PBS, the cells were incubated with primary antibodies overnight at 4 °C. After washing with PBS, the cells were incubated with secondary antibodies for 1 h at room temperature in the dark. Finally, the slides were incubated with a mounting medium and DAPI (Abcam, ab104139) and then visualized using fluorescence confocal microscopy.

Animal studies

The protocol for the care and use of all animals in this study was followed in accordance with the guidelines of the Guangdong Animal Center for the ethical treatment of animals and approved by the Institutional Animal Care and Use Committee of Guangzhou Medical University. The xenograft models were established as previously described. Five-week-old nude BALB/c mice (female) were purchased from Vital River Laboratories (Beijing, China) and bred in the Specific Pathogen Free Animal Center of Guangzhou Medical University. Mice were randomly allocated to each group. MDA-MB-231 cells (2.5 × 10^6) in 200 µl of PBS were inoculated...
subcutaneously into the axillary area of nude mice. After a week of inoculation, tumor sizes were recorded every other day. On Day 14 after treatment, tumor xenographs were collected and weighed.

Immunohistochemistry (IHC)
Tumor xenograft sections were immunostained using a MaxVision kit (Maixin Biol, Fuzhou, China) according to the manufacturer’s instructions. Primary antibodies against RAI14, STAMBP, and Ki67 were used to detect protein expression. The results were analyzed by Image-Pro Plus 7 software. The relative staining intensity was normalized to that of the control group.

Patient selection
Human breast cancer tissues and adjacent tissues were collected from ten patients at the Affiliated Cancer Hospital and Institute of Guangzhou Medical University. STAMBP and RAI14 expression in ten pairs of paraffin-embedded specimens was measured. Written informed consent was obtained from all the participants, and the study was approved by the Ethics Committee of the Affiliated Cancer Hospital and Institute of Guangzhou Medical University.

Statistical analysis
The statistical significance between two groups was determined by Student’s t-tests. GraphPad Prism 9.0 software was used for statistical analyses, and a p value of less than 0.05 was regarded as significant. All data are presented as the mean ± SD of three independent experiments.

RESULTS
STAMBP favors TNBC progression
To identify the key DUBs driving TNBC progression, BT549 TNBC cells were transfected with 96 DUB siRNAs for 72 h, and then, cell viability was assayed (Fig. 1a). Among the top positive hits (Fig. 1b and Supplementary Fig. 1), USP47, OTUD7B, USP18, UCHL1, and SENP2 have been previously reported to be associated with breast cancer growth, validating the effectiveness of our screening. Notably, the highest-scoring gene that was essential for the proliferation of BT549 cells encoded STAMBP (Fig. 1b), highlighting a unique role for STAMBP in controlling the growth of TNBC cells.

To assess the contribution of STAMBP to the progression of TNBC, we established two stable STAMBP-knockdown TNBC cell lines (the MDA-MB-231 and BT549 cell lines) and then assayed cell proliferation, migration, and invasion. Consistent with the siRNA screening data, the downregulation of STAMBP (Fig. 1c) significantly inhibited the proliferation of the MDA-MB-231 and BT549 cells (Fig. 1d). The wound healing (Fig. 1e) and Transwell assays (Fig. 1f) further demonstrated that the silencing of STAMBP impaired the migration and invasion of RAI14-knockdown cells. The hypothesis that STAMBP mediates tumor cell growth, invasion, and migration was confirmed by the overexpression of STAMBP after gene transfection (Fig. 1g-j). The results of these two-way interventions provide strong evidence supporting the tumor-promoting effect of STAMBP in TNBC.

STAMBP interacts with RAI14
Since STAMBP is a DUB, we next used immunoprecipitation in combination with mass spectrometry (IP-MS) to discover substrates for STAMBP involving the TNBC phenotype (Fig. 2a). The IP-MS analysis revealed that four proteins (RBM14, RAI14, LIMA1, and PABPC1) were the top candidates for STAMBP-binding proteins (Fig. 2b). To determine whether STAMBP affects the expression of these candidates, the protein expression of RBM14, RAI14, LIMA1, and PABPC1 was measured by Western blotting in control and STAMBP-knockdown cells. In MDA-MB-231 and BT549 cells, the knockdown of STAMBP resulted in the downregulation of RAI14 but not the downregulation of RBM14 or PABPC1 (Fig. 2c). STAMBP knockdown led to the downregulation of LIMA1 in BT549 cells but not in MDA-MB-231 cells (Fig. 2c, indicating a context-dependent role for STAMBP in the regulation of LIMA1 expression.

To further examine whether RAI14 acts as a direct substrate of STAMBP, we analyzed the interaction between STAMBP and RAI14. Co-IP assays demonstrated the endogenous interaction of STAMBP and RAI14 in MDA-MB-231 and BT549 cells (Fig. 2d). The colocalization of STAMBP and RAI14 was also observed in MDA-MB-231 and BT549 cells via immunofluorescence assays (Fig. 2e). Considering these results, we concluded that STAMBP directly interacts with RAI14 in TNBC cells.

STAMBP stabilizes RAI14 by decreasing its ubiquitination
To confirm the hypothesis that STAMBP regulates the stability of the RAI14 protein, we first ruled out the possibility that STAMBP affects the expression of RAI14 mRNA. qPCR assays showed that the knockdown of STAMBP exerted little or no effect on the mRNA level of RAI14 in MDA-MB-231 and BT549 cells (Fig. 3a). In contrast, the knockdown of STAMBP accelerated RAI14 protein turnover to a greater extent than control shRNA (Fig. 3b). The UPS and autophagy are the two major protein quality control systems in eukaryotic cells, and they share some common signaling pathways and substrates26. To determine which degradation system is critical for the degradation of RAI14 in TNBC cells, the effects of the proteasome inhibitor MG132 and the autophagy inhibitor bafilomycin A1 were analyzed. MG132, but not bafilomycin A1, effectively induced the accumulation of RAI14 protein in MDA-MB-231 and BT549 cells (Fig. 3c), indicating that RAI14 was a substrate in the UPS. Consistently, MG132 increased the ubiquitination rate of RAI14 in MDA-MB-231 cells (Fig. 3d). Importantly, MG132 blocked the degradation of RAI14 protein in STAMBP-knockdown MDA-MB-231 cells (Fig. 3e). These results indicated that STAMBP promoted the protein stabilization of RAI14 in TNBC cells.

Although polyubiquitin chains take different forms, K48-linked ubiquitination chains play a major role in proteasomal
We found that the knockdown of STAMBP increased the total ubiquitination and K48-linked ubiquitination rates of RAI14 in MDA-MB-231 cells (Fig. 3f), supporting a key role for STAMBP in RAI14 deubiquitination. In contrast, overexpression of STAMBP increased RAI14 protein expression (Fig. 3g) and decreased the ubiquitination rate of RAI14 in MDA-MB-231 cells (Fig. 3h). As expected, overexpression of STAMBP rescued the ubiquitination of RAI14 caused by STAMBP knockdown (Fig. 3i). However, overexpression of STAMBP with a catalytically inactive site (D348A) failed to decrease the ubiquitination of the RAI14 protein (Supplementary Fig. 2), supporting the hypothesis that STAMBP DUB activity is required for RAI14 deubiquitination. Collectively, these findings indicated that STAMBP stabilized RAI14 by decreasing its ubiquitination.

RAI14 is required for STAMBP-mediated TNBC growth

We next asked whether RAI14 plays a key role in STAMBP-mediated TNBC progression. The HA-RAI14 plasmid was stably expressed in control or STAMBP-knockdown MDA-MB-231 and BT549 cells (Fig. 4a). The overexpression of RAI14 released the inhibition on cell proliferation (Fig. 4b), cell migration (Fig. 4c) and cell invasion (Fig. 4d) in STAMBP-knockdown cells. To further characterize the role of RAI14 in TNBC cells, we used two nonoverlapping siRNAs to suppress RAI14 expression in MDA-MB-231 and BT549 cells (Fig. 5a). We observed that phenotypes in the RAI14-knockdown cells were similar to those in STAMBP-knockdown cells in terms of proliferation (Fig. 5b), migration (Fig. 5c), and invasion (Fig. 5d). In addition, STAMBP was stably overexpressed in control and RAI14-knockdown MDA-MB-231 and BT549 cells (Supplementary Fig. 3a). Overexpression of STAMBP released RAI14 knockdown-induced inhibition of cell proliferation (Supplementary Fig. 3b), cell migration (Supplementary Fig. 3c) and cell invasion (Supplementary Fig. 3d). Overall, these results indicated that RAI14 was a downstream effector of STAMBP that maintained the TNBC phenotype.

To further illuminate the underlying mechanisms of the downstream effect of the STAMBP-RAI14 pathway in TNBC cells, we performed an RNA sequencing analysis in control and RAI14-knockdown cells. Compared with control cells, there were 450 downregulated genes and 375 upregulated genes in the RAI14-knockdown cells (fold change ≥2; p < 0.05) (Fig. 5e). A subsequent comparison of gene expression differences (Fig. 5f) and a Gene Ontology (GO) analysis revealed that the knockdown of RAI14 affected multiple pathways, especially cell adhesion molecule-binding activity in molecular function (Fig. 5g), which is closely related to malignant transformation, cancer cell migration, and...
A similar trend was observed in the STAMBP-knockdown cells, which showed altered expression of most cell adhesion-related genes (25/40), and these changes were reversed by RAI14 overexpression (Supplementary Fig. 4). It has been reported that cell adhesion changes play an important role in regulating the epithelial-to-mesenchymal transition (EMT)\textsuperscript{29}. EMT is known to maintain cancer development and metastasis; therefore, we further examined whether RAI14 regulates the EMT in TNBC. We found that knocking down RAI14 increased the levels of epithelial markers, such as E-cadherin, and decreased
those of mesenchymal markers, such as slug, vimentin, and MMP9, in MDA-MB-231 cells (Fig. 5h). Similarly, knocking down STAMBP also inhibited EMT-like changes, and this effect was reversed by overexpression of RAI14 (Supplementary Fig. 5). Taken together, these findings demonstrated that RAI14 was critical for the STAMBP-mediated cell growth of TNBC cells.

The STAMBP-RAI14 pathway drives tumor growth in vivo
To study the effect of the STAMBP-RAI14 pathway on tumor growth in vivo, we injected control or STAMBP-knockdown MDA-MB-231 cells stably expressing HA-RAI14 into the axillary area of BALB/c nude mice to establish a xenograft model. The STAMBP-knockdown group showed reduced xenograft tumor growth (Fig. 6a), which was accompanied by a reduction in tumor volume (Fig. 6b) and tumor weight (Fig. 6c). Similar to the protumor effect of RAI14 in vitro, the overexpression of RAI14 reversed the xenograft tumor reduction caused by the knockdown of STAMBP to a certain extent (Fig. 6a–c). Furthermore, the protein level of the proliferation marker Ki67 was significantly decreased by STAMBP knockdown, but this effect was reversed by RAI14 overexpression (Fig. 6d). These animal results demonstrated that STAMBP promoted TNBC progression partially by sustaining RAI14 expression in vivo.

STAMBP expression predicts poor prognosis in TNBC patients
To further explore the clinical relevance of STAMBP expression in human breast cancer, we used the UALCAN database (http://ualcan.path.uab.edu/)30 to investigate the mRNA level of STAMBP in breast tumor tissues with respect to lymph node metastasis status and individual cancer stages. Compared with normal tissues, the expression of STAMBP was significantly higher in human breast tumor tissues, especially in human TNBC tissues (Fig. 7a). Moreover, compared with that in normal tissues, the level of STAMBP mRNA in breast cancer tissues of breast cancer patients with or without lymph node metastasis was increased (Fig. 7b). However, no significant difference was found between the patients with (N1/N2/N3) and without (N0) lymph node metastasis (Fig. 7b). In addition, compared with that in normal tissue, the level of STAMBP mRNA in breast cancer tissues in patients with Stage 1, 2, 3, or 4 breast cancer was increased (Fig. 7c). STAMBP showed higher expression in advanced clinical Stage 2 than in Stage 1 (Fig. 7c). However, the level of STAMBP did not significantly differ between the other stage groups. These findings confirm that STAMBP protein expression was highly expressed in tumor tissue from breast cancer patients.

We then used publicly available databases (www.kmplot.com)31 to evaluate the prognostic effect of STAMBP mRNA expression in TNBC patients. TNBC patients with higher STAMBP mRNA expression showed a lower overall survival (Fig. 7d). To investigate whether STAMBP and RAI14 proteins show similar clinical significance, we analyzed their protein expression levels in human TNBC and adjacent tissues (n = 10) via immunochemistry analysis. Compared with that in adjacent tissues, the protein expression of STAMBP or RAI14 was upregulated in human TNBC tissues (Fig. 7e). In addition, STAMBP protein expression was positively correlated with RAI14 protein expression in human TNBC tissues (Fig. 7f). These bioinformatics and immunohistochemical analyses indicated that the upregulation of STAMBP was related to the development of TNBC.

**DISCUSSION**
Due to the lack of three known therapeutic targets (ER, PR, and Her-2), TNBC is a challenging female tumor to study and treat. An in-depth understanding of the growth and invasion signaling in TNBC may lead to the development of new therapeutic targets. In this study, our unbiased siRNA and substrate screening revealed a previously unknown role of STAMBP in TNBC: STAMBP direct removes ubiquitin from RAI14, enhancing the stability of tumor-promoting RAI14 (Fig. 8). Since STAMBP and RAI14 are over-expressed in TNBC, our findings may establish a novel strategy to inhibit TNBC growth and invasion. DUBs are proteases that cleave ubiquitin moieties from substrates and have been implicated in various pathways of tumor biology. Accordingly, DUBs are key therapeutic targets for cancer therapy. Compared with that in other cancers, the direct role of DUB in TNBC is still poorly understood. In the current study, we proved that STAMBP is the most significant DUB gene associated with the growth of TNBC. Our analysis of public datasets and clinical specimens provides further support for findings suggesting that STAMBP may contribute to the tumor progression of TNBC. Performing functional experiments, we further demonstrated that the upregulation of STAMBP promoted the proliferation and invasion of TNBC cells, while the knockdown of STAMBP suppressed the malignant progression of TNBC cells. Previous studies have shown that STAMBP promotes the migration and invasion of lung cancer36 and melanoma cells.19 In line with these studies, we provide the first evidence that STAMBP is a potential target for the treatment of TNBC. Identifying tumor-related protein substrates is a challenge in UPS applications. Early studies have shown that STAMBP participates in the deubiquitination of several proteins, including NALP715, NLRP316, ULK117, and EGFR18, under different conditions. Our IP–MS analysis revealed that RAI14 is a common protein-binding partner of STAMBP in TNBC cells. Subsequent experiments showed that RAI14 is a substrate of the UPS and that its ubiquitination and proteasomal degradation are regulated by STAMBP. RAI14, also known as NORPEG, was first found in human retinal pigment epithelial cells (ARPE-19), and it was found to be induced by all-trans-retinoic acid. In addition to its physiological functions, dysfunctional RAI14 contributes to the development of multiple cancers, including glioblastoma,14 gastric cancer,15 melanoma,16 esophageal cancer,17, and breast cancer.18 Our in vitro and in vivo experiments not only showed that RAI14 contributes a phenotype similar to that associated with STAMBP but also demonstrated that RAI14 overexpression reversed the inhibition of proliferation and migration that had been induced by STAMBP knockdown. Although our data establish a new STAMBP-RAI14 pathway, the effects of other known STAMBP substrates in TNBC require further study.

Our RNA sequencing, in combination with GO enrichment analysis, indicated that RAI14 is closely associated with the cell adhesion pathway. Homeostasis in healthy tissues greatly...
Fig. 6  The STAMBP-RAI14 pathway regulates the development of TNBC in vivo. a–c Tumor xenografts were established in BALB/c nude mice using MDA-MB-231 cells stably transfected with STAMBP shRNA #1 or overexpressing HA-RAI14. Tumor size was recorded every other day. Tumor size (a), tumor images (b), and tumor weight (c) are shown (7 mice/group). The mean ± SD (n = 7), *p < 0.05. d Representative image of immunohistochemical staining for Ki67, RAI14, and STAMBP in nude mouse tumor tissues (200×). Scale bars: 50 μm. Ki67, RAI14, and STAMBP staining intensities were quantified with Image-Pro Plus 7 software. Mean ± SD (n = 7), *p < 0.05. ns, not significant.
Fig. 7  **STAMBP expression predicts poor prognosis in TNBC.**  

**a** Boxplot showing the relative expression of STAMBP in normal and breast cancer samples using the UALCAN web resource.  

**b** Box plot showing the relative expression of STAMBP in breast cancer based on nodal metastasis status using the UALCAN web resource.  

**c** Box plot showing the relative expression of STAMBP in breast cancer based on individual cancer stages using the UALCAN web resource. The mean ± SD. *p* < 0.05. ns, not significant.  

**d** Association between STAMBP expression and breast cancer patient survival. Data analyses were performed using Kaplan–Meier Plotter.  

**e** Representative images of STAMBP or RAI14 expression in human TNBC tissues (*n* = 10) and adjacent tissues (*n* = 10). Scale bars: 50 μm. The STAMBP or RAI14 staining intensity was quantified with Image-Pro Plus software (right graph). The mean ± SD (*n* = 10). *p* < 0.05.  

**f** The correlation of STAMBP and RAI14 expression in the tumor (*n* = 10).
other studies have shown that BC-1471 exerted no inhibitory Nevertheless, specific STAMBP inhibitors need to be developed before the translation of targetable STAMBP into medical applications for cancer is realized. In summary, our results revealed a previously unrecognized molecular link between UPS and TNBC mediated through STAMBP. Further understanding of STAMBP-dependent RAI14 protein stability may guide the development of improved strategies for the treatment of metastatic cancer, including TNBC.

Fig. 8 A working model of STAMBP action in TNBC. STAMBP, which is highly expressed in TNBC, exerts its oncogenic effect by inhibiting RAI14 ubiquitination and enhancing RAI14 stabilization, thereby possibly promoting cell adhesion remodeling and EMT in TNBC.

depends on cell–cell adhesion and cell–extracellular matrix interactions. In addition, cell adhesion plays a key role in the development of tumor recurrence, invasiveness, and distant metastasis. RAI14 is a member of the ankyrincor family and is related to the cortical actin cytoskeleton structure, cell–cell adhesion sites, and stress fibers. Our results indicate that STAMBP may drive the proliferation and invasion of TNBC by regulating the RAI14-mediated cell adhesion pathway, thereby providing a theoretical basis for the potential targeting of RAI14 protein degradation in the treatment of metastatic breast cancer. Studies have shown that pharmacologic inhibition of DUBs exerts a significant antineoplastic effect on various tumor cells. For example, the proteasomal DUB (USP14 and UCHL5) inhibitor VLX1570 has been entered in phase I trials for the treatment of multiple myeloma. BC-1471 is a small-molecule inhibitor against the catalytic activity of STAMBP, which may reduce the level of its substrate NALP7 protein in THP-1 cells. However, other studies have shown that BC-1471 exerted no inhibitory effect on STAMBP-mediated ubiquitination deconjugation or STAMBP-mediated EGFR stabilization in vitro. Similarly, we found that BC-1471 exerted no obvious effects on the viability of MDA-MB-231 cells (Supplementary Fig. 6a) or the degradation of RAI14 (Supplementary Fig. 6b) at the reported effective concentration. Nevertheless, specific STAMBP inhibitors need to be developed before the translation of targetable STAMBP into medical applications for cancer is realized.

In summary, our results revealed a previously unrecognized molecular link between UPS and TNBC mediated through STAMBP. Further understanding of STAMBP-dependent RAI14 protein stability may guide the development of improved strategies for the treatment of metastatic cancer, including TNBC.

REFERENCES
1. Ferlay, J. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer https://doi.org/10.1002/ijc.33588 (2021).
2. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
3. Cao, L. & Niu, Y. Triple negative breast cancer: special histological types and emerging therapeutic methods. Cancer Biol. Med. 17, 293–306 (2020).
4. Bai, X., Ni, J., Beretov, J., Graham, P. & Li, Y. Triple-negative breast cancer therapeutic resistance: where is the Achilles’ heel? Cancer Lett. 497, 100–111 (2021).
5. Damgaard, R. B. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 28, 423–426 (2021).
6. French, M. E., Koehler, C. F. & Hunter, T. Emerging functions of branched ubiquitin chains. Cell Discov. 7, 6 (2021).
7. Wang, Y. S., Wu, K. P., Jiang, H. K., Karkute, P. & Chen, R. H. Branched Ubiquitination: detection methods, biological functions and chemical synthesis. Molecules 25, 5200 (2020).
8. Antao, A. M., Tyagi, A., Kim, K. S. & Ramakrishna, S. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers (Basel) 12, 1579 (2020).
9. Wang, J. et al. The deubiquitinase USP28 stabilizes the expression of RecQ family helicases and maintains the viability of triple negative breast cancer cells. J. Biol. Chem. 298, 101443 (2022).
10. Guan, X. et al. MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3-phospho-BAD pathway. Cell Death Discov. 8, 84 (2022).
11. He, J. et al. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy. Cell Death Dis. 10, 285 (2019).
12. Mevissen, T. E. T. & Komander, D. Mechanisms of deubiquitinase specificity and regulation. Annu. Rev. Biochem. 86, 159–192 (2017).
13. Davies, C. W., Paul, L. N. & Das, C. Mechanism of recruitment and activation of the endosome-associated deubiquitinase AMSH. Biochemistry 52, 7818–7829 (2013).
14. McDonell, L. M. et al. Mutations in STAMBP, encoding a deubiquitinating enzyme, cause microcephaly-capillary malformation syndrome. Nat. Genet. 45, 556–562 (2013).
15. Bednash, J. S. et al. Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity. Nat. Commun. 8, 15203 (2017).
16. Bednash, J. S. et al. The deubiquitinase STAMBP modulates cytokine secretion through the NLRP3 inflammasome. Cell Signal. 79, 109859 (2021).
17. Tian, S. et al. High-throughput screening of functional deubiquitinating enzymes in autophagy. Autophagy 17, 1367–1378 (2021).
18. Xu, H. et al. STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway. Neoplasia 23, 607–623 (2021).
19. Iwakami, Y., Yokoyama, S., Watanabe, K. & Hayakawa, Y. STAM-binding protein regulates melanoma metastasis through SLUG stabilization. Biochem. Biophys. Res. Commun. 507, 484–488 (2018).
20. Yan, D. et al. Regulation of Bax-dependent apoptosis by mitochondrial deubiquitinase USP30. Cell Death Discov. 7, 211 (2021).

21. Silvestrini, V. C. et al. Proteomics analysis reveals the role of ubiquitin specific protease (USP47) in epithelial to mesenchymal transition (EMT) induced by TGFbeta2 in breast cells. J. Proteom. 219, 103734 (2020).

22. Tang, J., Wu, Z., Tian, Z., Chen, W. & Wu, G. OTUD7B stabilizes estrogen receptor alpha and promotes breast cancer cell proliferation. Cell Death Dis. 12, 534 (2021).

23. Yan, Z., Zhou, G., Wang, X., Chen, W. & Gao, H. USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT/Skp2 pathway. Int. J. Oncol. 53, 371–383 (2018).

24. Liu, S. et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGF-beta-induced breast cancer metastasis. Clin. Cancer Res. 26, 1460–1473 (2020).

25. Gao, X., Wu, Y., Qiao, L. & Feng, X. SENP2 suppresses NF-kappaB activation and sensitizes breast cancer cells to doxorubicin. Eur. J. Pharmacol. 854, 179–186 (2019).

26. Pohl, C. & Dikic, I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 366, 818–822 (2019).

27. Davis, C., Spaller, B. L. & Matouschek, A. Mechanisms of substrate recognition by the 26S proteasome. Curr. Opin. Struct. Biol. 67, 161–169 (2021).

28. Janiszewska, M., Primi, M. C. & Izard, T. Cell adhesion in cancer: beyond the widening cell-cell adhesions. Mol. Biosyst. 10, 838–850 (2014).

29. Chandrashekar, D. S. et al. UALCANC: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649–658 (2017).

30. Gyorgy, B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput. Struct. Biotechnol. J. 19, 4101–4109 (2021).

31. Li, Y. & Reverter, D. Molecular mechanisms of DUBs regulation in signaling and disease. Int. J. Mol. Sci. 22, 986 (2021).

32. Kutty, R. K. et al. Molecular characterization and developmental expression of NORPEG, a novel gene induced by retinoic acid. J. Biol. Chem. 276, 2831–2840 (2001).

33. Shen, X. et al. Retinoic acid-induced protein 14 (RAI14) promotes mTOR-mediated inflammation under inflammatory stress and chemical hypoxia in a U87 glioblastoma cell line. Cell Mol. Neurobiol. 39, 241–254 (2019).

34. Chen, C. et al. Knockdown of RAI14 suppresses the progression of gastric cancer. Onco Targets Ther. 11, 6693–6703 (2018).

35. Liu, F. et al. Long non-coding RNA AFAP1-A51 accelerates the progression of melanoma by targeting mir-653-5p/RAI14 axis. BMC Cancer 20, 258 (2020).

36. Wang, J. et al. RAI14 silencing suppresses progression of esophageal cancer via the STAT3 pathway. Aging (Albany NY) 12, 18084–18098 (2020).

37. Gu, M. et al. Downregulation of RAI14 inhibits the proliferation and invasion of breast cancer cells. J. Cancer 10, 6341–6348 (2019).

38. Chaudhuri, O., Cooper-White, J., Janney, P. A., Mooney, D. J. & Shenoy, V. B. Effects of extracellular matrix viscoelasticity on cellular behaviour. Nature 584, 535–546 (2020).

39. Qian, X., Mruk, D. D., Cheng, Y. H. & Cheng, C. Y. RAI14 (retinoic acid induced protein 14) is an F-actin regulator: Lesson from the testis. J. Biol. Chem. 2505 (2019).

40. Wang, X. et al. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem. Biol. Drug Des. 86, 1036–1048 (2015).

41. Rendin, E. K. et al. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest. N. Drugs 38, 1448–1453 (2020).

42. Guo, Y. et al. Structural and functional characterization of ubiquitin variant inhibitors for the JAMM-family deubiquitinases STAMBP and STAMBPL1. J. Biol. Chem. 297, 101107 (2021).

ACKNOWLEDGEMENTS
The study was supported by the Basic and Applied Basic Research Project of the Guangdong Basic Research Program (202201011411), NSFC (Nos. 81802405, 81602427, 81772492, 82272660, and 81900365), the National Funds for Developing Local Colleges and Universities (B16056001), Natural Science Foundation Research Team of Guangdong Province (2018B030312001, 2017A030310151, and 2016A030310281), the Science and Technology Program of Guangzhou (201604020001), the Innovative Academic Team of the Guangzhou Education System (1201610014), and the Research Team of Department of Education of Guangdong Province (2017KXTD027).

AUTHOR CONTRIBUTIONS
J.L. and X.C. designed the whole research project, analyzed all results, and wrote the paper. Q.Y. participated in all experiments and contributed to the paper. D.Y., C.Z., Q.X., Q.H., S.L., and X.L. participated in the experiments. D.T. helped in revising this paper.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s12276-022-00890-1.

Correspondence and requests for materials should be addressed to Xin Chen or Jinhao Liu.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

Experimental & Molecular Medicine (2022) 54:2047 – 2059